Tilray | TRLY - 销售和管理费用

金融业

USD 3.83

USD 2.1B

现金及等价物

USD 264.83M

USD 164.37M

USD 729.32M

USD 259.32M

USD 640.95M

USD -20.01M

USD 8.37M

USD 2.84K

EPS每股收益

USD -0.41

股本和储备

USD 1.58B

USD 57.47M

债务利息支出

USD 6.7M

USD 12.83M

USD 268.59M

USD 2.92B

USD -44.93M

USD 237.52M

USD -20.01M

普通股股本

USD 116.52M

11.57

USD -39.96M

USD 217.51M

销售和管理费用

USD 24.85M

USD 282.79M

贸易债权人

USD 114.5M

应收帐款人

USD 109.07M

	销售和管理费用	更改		日
Acasti Pharma	USD 1.96M		180K	2025-09
Akebia Therapeutics	USD 23.53M		3.19M	2025-12
Alaunos Therapeutics	USD 447K		138K	2026-03
Aurora Cannabis	CAD 41.4M		781K	2026-03
Avita Medical	AUD 19.03M		1.95M	2025-12
Canopy Growth	CAD 31.17M		2.27M	2026-03
Cronos Group	USD 17.59M		237K	2026-06
Dianthus Therapeutics	USD 12.47M		5.89M	2026-03
Divis Laboratories Ltd	INR 3.4B		10M	2025-06
Ionis Pharmaceuticals	USD 130.07M		20.92M	2026-06
IQVIA Holdings	USD 574M		72M	2026-06
Knight Therapeutics	CAD 35.45M		4.43M	2025-12
Moderna	USD 216M		43M	2026-06
Organigram Holdings	CAD 22.01M		14.28M	2026-03
Organon & Co	USD 434M		10M	2026-06
Revvity	USD 278.58M		24.69M	2026-06
Tectonic Therapeutic	USD 6.43M		2.99M	2026-03
Tilray	USD 24.85M		1.7M	2025-09
Viatris	USD 1.13B		205.7M	2026-06
Xeris Pharmaceuticals	USD 53.14M		10.51M	2026-03
Zealand Pharma A/S	104M		12.19M	2026-03